Stock SNGX SOLIGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Soligenix, Inc.

Equities

SNGX

US8342235053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 08:13:09 01/05/2024 pm IST 		5-day change 1st Jan Change
0.403 USD +3.33% Intraday chart for Soligenix, Inc. +5.74% -46.51%
25/04 Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa CI
15/04 Sector Update: Health Care Stocks Softer Late Afternoon MT

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Number of employees: 14

Sales per Business

USD in Million2022Weight2023Weight Delta
Public Health Solutions
52.9 %
1 96.6 % 0 52.9 % -51.55%
Specialized BioTherapeutics
47.1 %
0 3.4 % 0 47.1 % +1,137.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 1 100.0 % -11.55%

Managers

Managers TitleAgeSince
Christopher Schaber CEO
 Chief Executive Officer 57 01/06/01
Jonathan Guarino DFI
 Director of Finance/CFO 51 11/19/11
Richard Straube CTO
 Chief Tech/Sci/R&D Officer 72 06/14/06
Oreola Donini CTO
 Chief Tech/Sci/R&D Officer 52 15/13/15
Adam T. Rumage LAW
 General Counsel - 01/07/01

Members of the board

Members of the board TitleAgeSince
Christopher Schaber CEO
 Chief Executive Officer 57 01/06/01
Gregg Lapointe BRD
 Director/Board Member 65 01/09/01
Robert Rubin BRD
 Director/Board Member 78 01/09/01
Jerome Zeldis BRD
 Director/Board Member 74 22/11/22
Diane Parks BRD
 Director/Board Member 72 08/19/08

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,241,837 14,231,250 ( 99.93 %) 0 99.93 %

Shareholders

NameEquities%Valuation
Renaissance Technologies LLC
0.8817 %
92,792 0.8817 % 55 675 $
BlackRock Institutional Trust Co. NA
0.7663 %
80,651 0.7663 % 48 391 $
Vanguard Group, Inc. (Subfiler)
0.4833 %
50,865 0.4833 % 30 519 $
Geode Capital Management LLC
0.4769 %
50,196 0.4769 % 30 118 $
Timothy Coté
0.2406 %
25,317 0.2406 % 15 190 $
First Wilshire Securities Management, Inc.
0.2217 %
23,334 0.2217 % 14 000 $
Warberg Asset Management LLC
0.1900 %
20,000 0.1900 % 12 000 $
Citadel Securities GP LLC
0.1686 %
17,743 0.1686 % 10 646 $
FNY Investment Advisers LLC
0.1425 %
15,000 0.1425 % 9 000 $
Two Sigma Investments LP
0.1115 %
11,734 0.1115 % 7 040 $

Company contact information

Soligenix, Inc.

29 Emmons Drive Suite B-10

08540-5919, Princeton

+(609) 538-8200

http://www.soligenix.com
address Soligenix, Inc.(SNGX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Ratings for Soligenix, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.39 USD
Average target price
3.5 USD
Spread / Average Target
+797.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SOLIGENIX, INC. Stock Soligenix, Inc.
-46.51% 5.55M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.02% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.55% 96.09B
ARGENX SE Stock argenx SE
+2.13% 22.28B
BIONTECH SE Stock BioNTech SE
-17.15% 21.4B
GENMAB A/S Stock Genmab A/S
-8.98% 18.14B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.29% 16.09B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.73% 13.83B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.02% 11.97B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SNGX Stock
  4. Company Soligenix, Inc.